PK, Safety,and Efficacy of Omacetaxine in Patients With Chronic Myeloid Leukemia

Study Title
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Teva Identifier
C41443/2057 | 2013-005320-42
ClinicalTrials.gov Identifier
NCT02078960
Study Status
Terminated
Trial Condition(s)
Chronic Myeloid Leukemia
Interventions
Drug: Omacetaxine mepesuccinate

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years and older
Trial Duration
October 9, 2014 - November 27, 2017
Phase
Phase 1/2

Study Type

Interventional